|
|
Article: AGY Therapeutics Series C: $31.3M For Three Programs.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
AGY Therapeutics Inc. netted $31.3 million in a Series C financing for its work with small molecules against ischemic stroke and Alzheimer's disease, predicting it will have a product ready for the clinic "toward the second half of next year," said Karoly Nikolich, founder and CEO.
"These are targets that are currently in drug screening, and one program in the brain tumor area is getting ready for therapeutic antibody development," followed by programs in stroke and Alzheimer's disease, he said.
Although the brain tumor effort seems in the lead position, he added, "I have to say that, with a little bit of luck, it could be ...
Related newspaper, magazine, and journal articles:
|
|
Article: TOLERRX RAISES $31M IN SERIES D TO ADVANCE DIABETES DRUG TRX4.
BIOWORLD Today;
March 30, 2005 ;
700+ words
... ... antibody that is partnered with South San Francisco-based Genentech Inc. It has completed ... New York-based Bear Stearns Health Innoventures led the $31 million round, which ... general partner of Bear Stearns Health Innoventures, to its board, and it has hired ...
|
|